IDNA vs. CANC
Compare and contrast key facts about iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Tema Oncology ETF (CANC).
IDNA and CANC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. CANC is an actively managed fund by Tema. It was launched on Aug 14, 2023.
Performance
IDNA vs. CANC - Performance Comparison
Loading graphics...
IDNA vs. CANC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 11.45% | 17.26% | -0.72% | -7.63% | -42.28% | -13.11% |
CANC Tema Oncology ETF | 6.91% | 42.92% | -5.37% | 510.51% | -85.34% | -51.82% |
Returns By Period
In the year-to-date period, IDNA achieves a 11.45% return, which is significantly higher than CANC's 6.91% return.
IDNA
- 1D
- 0.48%
- 1M
- -5.56%
- YTD
- 11.45%
- 6M
- 20.68%
- 1Y
- 48.06%
- 3Y*
- 9.03%
- 5Y*
- -7.93%
- 10Y*
- —
CANC
- 1D
- 1.16%
- 1M
- -0.89%
- YTD
- 6.91%
- 6M
- 27.17%
- 1Y
- 58.38%
- 3Y*
- 140.92%
- 5Y*
- —
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IDNA vs. CANC - Expense Ratio Comparison
IDNA has a 0.47% expense ratio, which is lower than CANC's 0.75% expense ratio.
Return for Risk
IDNA vs. CANC — Risk / Return Rank
IDNA
CANC
IDNA vs. CANC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IDNA | CANC | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.75 | 2.17 | -0.42 |
Sortino ratioReturn per unit of downside risk | 2.40 | 2.84 | -0.44 |
Omega ratioGain probability vs. loss probability | 1.29 | 1.36 | -0.07 |
Calmar ratioReturn relative to maximum drawdown | 3.66 | 4.37 | -0.71 |
Martin ratioReturn relative to average drawdown | 11.65 | 15.21 | -3.56 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| IDNA | CANC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.75 | 2.17 | -0.42 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.28 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.11 | -0.04 | +0.14 |
Correlation
The correlation between IDNA and CANC is 0.55, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
IDNA vs. CANC - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 1.06%, more than CANC's 0.05% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.06% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% |
CANC Tema Oncology ETF | 0.05% | 0.06% | 3.00% | 0.56% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
IDNA vs. CANC - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for IDNA and CANC.
Loading graphics...
Drawdown Indicators
| IDNA | CANC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.26% | -97.53% | +29.27% |
Max Drawdown (1Y)Largest decline over 1 year | -12.11% | -12.40% | +0.29% |
Max Drawdown (5Y)Largest decline over 5 years | -68.26% | — | — |
Current DrawdownCurrent decline from peak | -45.05% | -55.68% | +10.63% |
Average DrawdownAverage peak-to-trough decline | -36.05% | -73.89% | +37.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.81% | 3.57% | +0.24% |
Volatility
IDNA vs. CANC - Volatility Comparison
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a higher volatility of 9.54% compared to Tema Oncology ETF (CANC) at 8.20%. This indicates that IDNA's price experiences larger fluctuations and is considered to be riskier than CANC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| IDNA | CANC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.54% | 8.20% | +1.34% |
Volatility (6M)Calculated over the trailing 6-month period | 18.22% | 16.22% | +2.00% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.75% | 27.19% | +0.56% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.53% | 285.53% | -257.00% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.68% | 285.53% | -255.85% |